Pimozide

• Description :

  Pimozide is a dopamine receptor antagonist, with Kis of 1.4 nM, 2.5 nM and 588 nM for dopamine D2, D3 and D1 receptors, respectively, and also has affinity at α1-adrenoceptor, with a Ki of 39 nM; Pimozide also inhibits STAT3 and STAT5.

• Product Name Alternative :

  R6238

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  Adrenergic Receptor; Dopamine Receptor; Parasite; STAT

• Type :

  Reference compound

• Related Pathways :

  Anti-infection; GPCR/G Protein; JAK/STAT Signaling; Neuronal Signaling; Stem Cell/Wnt

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer; Neurological Disease; Endocrinology

• Assay Protocol :

  https://www.medchemexpress.com/Pimozide.html

• Concentration :

  10mM

• Purity :

  99.91

• Solubility :

  DMSO : 16.67 mg/mL (ultrasonic)

• Smiles :

  O=C1NC2=CC=CC=C2N1C3CCN(CCCC(C4=CC=C(F)C=C4)C5=CC=C(F)C=C5)CC3

• Molecular Formula :

  C28H29F2N3O

• Molecular Weight :

  461.55

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Ybema CE, et al. Adrenoceptors and dopamine receptors are not involved in the discriminative stimulus effect of the 5-HT1A receptor agonist flesinoxan. Eur J Pharmacol. 1994 Apr 21;256 (2) :141-7.|[2]Cai N, et al. The STAT3 inhibitor pimozide impedes cell proliferation and induces ROS generation in human osteosarcoma by suppressing catalase expression. Am J Transl Res. 2017 Aug 15;9 (8) :3853-3866. eCollection 2017.|[3]Erik A. Nelson, et al. The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors. Blood. 2011 Mar 24; 117 (12) : 3421-3429.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Launched

• Isoform :

  STAT3; STAT5

• CAS Number :

  [2062-78-4]